Drug interactions
Arformoterol + Indacaterol-glycopyrronium
Severity: Major
Arformoterol and Indacaterol-glycopyrronium: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both agents are inhaled long-acting beta-2 agonists (indacaterol is one component of the combination), so using them together duplicates therapy and adds to beta-adrenergic cardiovascular effects. This can cause tachycardia, hypokalemia, QTc prolongation and arrhythmia.
What this interaction means in plain words
Arformoterol and Indacaterol-glycopyrronium can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Arformoterol belongs to Respiratory; Indacaterol-glycopyrronium belongs to Respiratory.
Why it happens
Additive beta-2 adrenergic stimulation leading to hypokalemia, tachycardia and QT prolongation.
What to do
Avoid concurrent use of two long-acting beta-agonists and keep a single LABA-containing regimen. If a switch is made, stop one agent and monitor heart rate, potassium and ECG as indicated.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Arformoterol and Indacaterol-glycopyrronium, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Indacaterol-glycopyrronium
Other interactions of Arformoterol
Frequently asked questions
Can I take Arformoterol with Indacaterol-glycopyrronium?
MediHelp rates the interaction as major. Arformoterol and Indacaterol-glycopyrronium can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both agents are inhaled long-acting beta-2 agonists (indacaterol is one component of the combination), so using them together duplicates therapy and adds to beta-adrenergic cardiovascular effects. This can cause tachycardia, hypokalemia, QTc prolongation and arrhythmia.
How serious is the interaction between Arformoterol and Indacaterol-glycopyrronium?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use of two long-acting beta-agonists and keep a single LABA-containing regimen. If a switch is made, stop one agent and monitor heart rate, potassium and ECG as indicated.
What other medicines interact with Indacaterol-glycopyrronium?
MediHelp also lists interactions of Indacaterol-glycopyrronium with, for example, Amisulpride, Arsenic trioxide, Betaxolol. The full list is on the Indacaterol-glycopyrronium page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
